Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases

INTRODUCTION: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinelli, Sara, Granito, Alessandro, Piscaglia, Fabio, Renzulli, Matteo, Stagni, Angela, Bolondi, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830515/
https://www.ncbi.nlm.nih.gov/pubmed/24282421
http://dx.doi.org/10.5812/hepatmon.11721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830515/
https://www.ncbi.nlm.nih.gov/pubmed/24282421
http://dx.doi.org/10.5812/hepatmon.11721

Ejemplares similares